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PRESENTATION AGENDA 
• Present new results using a transthoracic 
bioimpedance monitoring system to detect 
heart failure decompensation 
• Discuss a smartphone-based arrhythmia 
detection system 
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WHAT IS HEART FAILURE? 
– A set of symptoms resulting from failure of the heart to pump blood to 
meet the metabolic demands of the body. 
– Diagnosis is defined by signs and symptoms.  
 No clear, straightforward diagnostic test for HF 
Respiratory problems 
Labored breathing 
Difficulty breathing when lying flat 
Paroxysmal nocturnal dyspnea 
Pulmonary edema 
Fatigue 
Exercise intolerance 
Edema 
Weight gain 
Distended neck veins 
Nausea 
Diminished appetite 
Excessive urination during night 
Fluid retention 
Angina 
Cardiac rhythm disorders 
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THE CHALLENGES OF HEART FAILURE 
MANAGEMENT 
Data source: AHA. Heart and Stroke Statistics – 2009 Update.  
Each year there are 1.1 million HF admissions in the US. The mean cost of each HF hospitalization is 
$18,000 
27% of HF patients re-hospitalized within 30 days; 50% within 6 months2 
Hospitals are penalized for early readmissions after HF hospitalization 
Pulmonary congestion is difficult to recognize in its early stages due to the late appearance of 
symptoms.3 Fluid accumulation is often detected too late to avert hospitalization4 
Weight monitoring has low patient compliance7 
670,000 5.8 million 287,000 
US Annual  
Incidence 
HF 
Prevalence 
Annual  
Mortality 
Annual 
Morbidity 
1.1 million 
admissions 
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MONITORING OPTIONS FOR HEART 
FAILURE PATIENTS 
– Traditional monitoring - Patient keeps a diary to self-monitor weight, blood pressure, and symptoms 
– Tele Monitoring – automated system to simplify the monitoring of weight, blood pressure, and symptoms 
 Large studies have shown that telemonitoring of symptoms, weight, and symptoms to clinics does not reduce HF-
related hospitalizations. 
– Implantable device remote monitoring – Implantable cardiac devices collect information which provide 
insights into HF progression 
e.g., ICD device with the capability to measure AF burden, heart rate variability, intra-thoracic impedance, or filling 
pressure changes 
Time 
Pressure 
changes 
Impedance 
change 
Autonomic 
adaptation 
Weight/BP changes, 
BNP, HF symptoms 
Decompensation 
Stable 
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Intrathoracic bioimpedance predicts HF decompensation 
The challenge 
• 1 in 3 of HF patients re-hospitalized within 30 
days 
• Clinical predictors show poor predictive 
capabilities 
Clinical observation* 
• PARTNERS-HF study - Patients with >=1 abnormal HF statistic trend 
have 5-fold higher risk for hospitalization within 30 days 
• Mid-HeFT study – Thoracic impedance monitoring is more reliable 
and detects fluid changes earlier than symptom onset 
Courtesy Medtronic and Biotronik, Inc 
HF MONITORING RE-EXAMINED 
• Currently, HF monitoring is 
restricted to patients with 
implantable devices 
• A minority of HF patients 
are eligible for such devices 
• New technologies are 
needed to monitor for acute 
decompensated HF (ADHF) 
• Might transthoracic 
bioimpedance work? 
 
Courtesy Medtronic and Philips, Inc 
FLUID ACCUMULATION VEST SYSTEM 
SENTINEL-HF: INTERIM ANALYSIS 
• We have recruited 107 
participants admitted with ADHF 
to UMMC 
• Participants are trained on the use 
of a FAV-smartphone dyad to 
obtain and transmit a 5-minute 
bioimpedance measurement once 
daily for 45-days after discharge.  
• Readmission and diuretic dosing 
adjustments are identified using 
participant report and causes 
adjudicated using medical records.  
• Daily bioimpedance is analyzed 
Courtesy Medtronic and Philips, Inc 
SENTINEL-HF STUDY: A REPRESENTATIVE HF 
COHORT 
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Demographics  
Age, y  67 ± 12 
Men 57% 
Race 
Caucasian  88% 
Other 12% 
Medical history 
Hypertension  76% 
Atrial fibrillation  46% 
Diabetes mellitus  51% 
Chronic lung disease  24% 
Coronary heart disease  22% 
Psychosocial characteristics  
Cognitively impaired 11% 
Depressed  17% 
Clinical characteristics  
Length of index hospital stay, days  5 ± 3  
Body mass Index, kg/m2  33 ± 10  
Ejection fraction, %  48% 
Discharge medications   
Aspirin  69% 
Loop diuretic 83% 
  ACE inhibitor/ARB 41% 
45-day outcomes 
HF-related rehospitalization  10% 
  Diuretic up-titration  10% 
INTERIM ANALYSIS RESULTS – SUCCESS RATE 
 
>= 75 %
< 75%
Relative number of successful measurements
 
 
>= 75 %: 17 patients
< 75%: 7 patients
• Despite their advanced 
age and high burden of 
comorbid diseases, study 
participants with ADHF 
were able to make daily 
bioimpedance 
measurements using a 
FAV and transmit them 
using a smartphone.  
• This proves the feasibility 
and acceptability of using 
HF monitors in the 
community 
TRANSTHORACIC BIOIMPEDANCE PREDICTS 
EARLY READMISSION FOR HF 
    
    
 
• Early readmission was 
common and predicted up to 7 
days in advance by an 
algorithm analyzing 
transthoracic bioimpedance.  
 
• Transthoracic bioimpedance 
monitoring may offer 
possibilities for reducing HF 
readmissions by enabling 
identification and treatment of 
outpatients with early HF 
decompensation 
ATRIAL FIBRILLATION: A COMPLEX DISEASE 
WITH FAR-REACHING IMPACT 
Miyasaka Circulation 2006;11:119; Go JAMA 2001;285:2370 
American Heart Association 
ATRIAL FIBRILLATION: A DISEASE 
DIAGNOSED USING TECHNOLOGY 
DEVELOPED IN 1903 
AUTOMATED AF DETECTION ALGORITHM 
DEVELOPMENT 
• Electrocardiographic data was 
obtained from consenting 
UMMHC patients with AF who 
wore Holter monitors (IRB-
Pro00000008)  
• Data from patients in MIT-BIH 
AF Database were also used 
• Time Varying Coherence 
Function, Root Mean Squared 
and Shannon Entropy examined 
 
TVCF of subject 8455 of the MIT-BIH 
AF database according to each beat 
and normalized frequency 
Lee, McManus, Chon. IEEE. 2013 
DEVELOPMENT OF A COMPREHENSIVE AUTOMATED 
ALGORITHM FOR DETECTION OF THE 3 MAJOR 
ATRIAL ARRHYTHMIAS 
AF MONITORING: A CHANGE IS NEEDED 
• AF is associated with 
high risk for stroke and 
hospitalization 
• AF can come and go 
(paroxysmal), leading 
to delays in diagnosis 
• New monitoring 
technologies are 
needed 
A mobile phone application for data recording using a camera 
(The application uses the camera lens and light to acquire 
information about heart rate and rhythm)  
(a) Green band PPG signal, (b) HRECG (thin black 
line) and HRGREEN (thick blue line) during 
spontaneous breathing, (c) HRV power spectral 
density plots from ECG (thin black line) and GREEN 
(thick blue line).    
AF DETECTION USING A SMARTPHONE 
AN IPHONE PROTOTYPE OF THE AF 
DETECTION APPLICATION 
McManus, Lee, Chon. HeartRhythm. 2013 
WE RECRUITED A COHORT OF 76 PATIENTS 
UNDERGOING CARDIOVERSION 
McManus, Lee, Chon. HeartRhythm. 2013 
A NOVEL APPLICATION RUNNING AN AF 
DETECTION ALGORITHM DETECTS AF 
McManus, Lee, Chon. HeartRhythm. 2013 
A SMARTPHONE APP CAN IDENTIFY AF 
• In a prosectively recruited 
cohort, we found that a novel 
algorithm analyzing signals from 
an iPhone 4S accurately 
distinguished pulse recordings 
during AF from sinus rhythm 
• NHLBI-funded study is underway 
to explore the acceptability and 
usability of the smartphone-
based application in the 
community 
 
McManus, Lee, Chon. HeartRhythm. 2013 
THANK YOU FOR ATTENDING! 
“Now this is not the 
end. It is not even 
the beginning of the 
end. But it is, 
perhaps, the end of 
the beginning.” 
Winston Churchill 
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